Hay fever isn't the only thing causing brand-name prescription
manufacturers' eyes to water this allergy season. Top-selling products for the
treatment of allergic rhinitis (AR) went off-patent during 2007, giving rise to
popular generic alternatives and subsequent losses of market share among
staples in the category. The situation has caused allergy brand sales to dip to
their lowest point in five years. Last year's sales were down 22% to $5.2
billion from 2006.
The sniffling pharmaceutical companies invested in allergy
relief will have to make tough decisions about where to put marketing dollars,
whether transitioning to over-the-counter sales (Zyrtec), concentrating on
replacement brands with fresh patents (Veramyst) or drumming up awareness for
potential pipeline possibilities (Claritin/Singulair).
Due to the seasonal nature of allergy affliction, marketing
efforts for AR products tend to focus on two peak seasons each year: spring
(April, May and June) and fall (September and October).
The two most prominent categories for AR treatment are oral
antihistamines (including combination antihistamines) and inhaled nasal
corticosteroids (INCs). Antihistamines are widely available OTC and are
relatively easy to use, although many physicians are recommending
corticosteroids to patients. “Based on research we conducted last fall, there
is a notable uptick in physicians prescribing INCs,” says Sue Ramspacher, SVP,
category business leader of respiratory, GfK Market Measures. “Inhaled nasal
corticosteroids are becoming the first line of therapy and are being used to a
much greater extent in terms of a physician's perspective. Veramyst is being
prescribed, for example, because it addresses a broader range of symptoms.”
New AR drugs like Veramyst, and Xyzal, in the antihistamine
category, have the ability to move quickly into positive sales figures.
“The AR market is driven by sampling and detailing,” says
Ramspacher. “Literally weeks after the launch of Xyzal, there was a high level
of awareness among allergists.”
Ramspacher also mentions that the eagerly anticipated Claritin/Singulair
pipeline compound is “at the top of the list in terms of physician awareness.”
The new compound was formed through a Schering-Plough/Merck partnership and is
currently seeking approval from the FDA. “[AR] is a crowded category with lots
of competitive players. Even though the market is crowded, there are still
needs to be met, and areas where product attributes could differentiate
themselves,” she says.
Ramspacher cites long-term safety and the absence of rebound
congestion as two examples of attributes that could provide differentiation.
This should be encouraging for companies itching to enter the market. However,
recent safety issues regarding Singulair may give pause to physicians. In
March, the FDA announced an investigation into a “possible association between
the use of Singulair and behavior/mood changes, suicidality (suicidal thinking
and behavior) and suicide.”
Approved in April 2007, GlaxoSmithKline's Veramyst
(fluticasone furoate) nasal spray is an emerging INC, which the company hopes
will help to offset Flonase's market share losses to generics. Flonase was once
a leader of the category. “GlaxoSmithKline will not be advertising Flonase at
all this season, on the consumer side or the professional side,” says Robin
Gaitens, product communications manager for GSK. A Veramyst TV spot from
September 2007 drew questions and commentary from viewers, who reacted to a
seemingly odd line of copy seen in the ad:
“The way Veramyst works is not entirely understood.” Gaitens
confirmed a 2008 DTC campaign in support of Veramyst, but declined to elaborate
on campaign details.
In September 2006, UCB and Sanofi-Aventis entered into an
agreement to launch and co-market the antihistamine Xyzal (levocetirizine
dihydrochloride) in the US. Xyzal received FDA approval in May 2007 for
tablets, followed by an oral solution in February 2008.
A DTC campaign featuring national TV spots, online and print
ads launched in March, according to Scott Ellis, product director, UCB.
“As part of the 2008 public relations program, the Xyzal
Challenge Your Course campaign was launched [in February], and is slated to run
throughout the entire year. We have implemented a comprehensive, integrated
consumer and professional awareness campaign for Xyzal as well, called X-Factor.”
An X-Factor print ad contains copy reading: “Your indoor and outdoor allergies
can itch, sneeze and run. But they can't hide.” The Challenge Your Course
(www.challengeyourcourse.com) program is a “collaborative partnership with the
Asthma and Allergy Foundation of America (AAFA) and Jill McGill, an LPGA golfer
who suffers from indoor and outdoor allergies,” explains Ellis. “The Xyzal
website will incorporate the PR spokesperson Jill McGill as an ‘interactive
guide,' detailing her experience as a nasal allergy sufferer.” Agencies working
on various aspects of the campaign include Ogilvy, HeartbeatDigital and PR
agency Biosector 2.
Companies without new products immediately available for
market are dealing with patent losses in other ways. Zyrtec (cetirizine HCl),
the nation's top-selling prescription allergy medicine, went off-patent in
December 2007. Pfizer ceded OTC manufacturing and marketing rights to McNeil
Consumer Healthcare in 2006. Zyrtec, an antihistamine, began its life as an OTC
in January, with in-store displays created by Henschel-Steinau Inc.
After a branded Spring Wonderland Dome was erected in New
York City's Central Park last January, McNeil most recently announced a
partnership with the Asthma and Allergy Foundation of America (AAFA) and
actress/comedian Molly Shannon. The campaign, “Allergies Are No Laughing
Matter,” represents “part of Zyrtec's overall educational campaign,” according
to McNeil spokesperson Peggy Ballman. Ballman declined to comment further on
advertising for the brand.
Schering-Plough is probably the most experienced in dealing
with an OTC crossover in the allergy category. Claritin was approved for OTC
back in 2002, and has continued to market its line of products. A new obstacle
surfaced in 2006 when an article in the Patriot Act banned all OTC sales of
products containing pseudoephedrine, a decongestant commonly used in
combination with AR medications. Claritin-D, and now Zyrtec-D, are consequently
held behind-the-counter (BTC), and represented on the drugstore shelf by
placards urging consumers to “Take this tag to the pharmacy for purchase.”
Commenting on the situation, Ramspacher explains that allergy medications are
now classified into three groups: prescription, OTC and BTC. “A notable
Schering-Plough ad for Claritin has a patient saying ‘Thank you for not
changing your formulation,' which is a direct statement on behind-the-counter
Marketing efforts for Claritin began targeting Zyrtec before
it reached the shelves.
A Schering-Plough company release from November 2007 emphasizes
Zyrtec's listed side effects this way: “While Zyrtec is approved for
over-the-counter sale, consumers should be aware of its common side effects
like drowsiness and fatigue. In fact, Zyrtec prescription labeling carries a
caution about the occurrence of drowsiness and urges consumers to exercise
caution when driving a car or operating dangerous machinery.” This
passive-aggressive technique was augmented in January with Schering-Plough's
announcement of a sponsorship agreement with “Allergy Sufferer and NASCAR
Sprint Cup Driver Carl Edwards.” In the release, Edwards says, “When I'm
driving at 180 miles per hour, I can't risk taking a medicine that makes me
drowsy. That's why I only use non-drowsy Claritin to treat my worst allergy
symptoms.” The Edwards sponsorship deal extends through the 2008 Sprint Cup
Competition from generics in the AR market will not subside
any time soon. Sanofi-Aventis's Allegra commanded 37% of the US antihistamine
market in 2005, but has seen a steady decline – generic Allegra is currently
the most prescribed antihistamine in the nation, capturing 36.2% of the market
share for that category, according to IMS Health.
One important factor catalyzing generic alternative usage is
the “doctor's offices vs managed care cost concerns,” says GfK's Ramspacher.
“Lots of generic competitors have been made available due to managed care
professionals seeking the lowest cost alternatives.”
According to recent data from the American Academy of
Allergy Asthma & Immunology, as many as 50 million people suffer from two
forms of AR: seasonal and perennial. Seasonal allergies are caused by tree,
grass and weed pollen. Perennial allergies are caused by frequent exposure to
allergens like animal dander, mold spores and dust mites.
Many top-sellers in the antihistamine category are moving
into old age, or at least middle age, in terms of patent life expiry. Meda
Pharmaceutical's Astelin (azelastine HCl) and Schering-Plough's Clarinex
(desloratadine) are both moving into the last couple of years of protection.
However, most of the best-selling INCs are in good shape in terms of patent
protection, with Flonase (fluticasone propionate) being the single exception to
the rule – Flonase expired in 2004. Nasacort AQ, the third best-seller in 2007,
expires in 2016, while AstraZeneca's Rhinocort Aqua, the fourth best-seller,
expires in 2017. Rhinocort Aqua won a MM&M award in 2007 for its “Rhino
Reader” campaign, created by Harte-Hanks. Generic Flonase was the
second-best seller in 2007, according to research conducted by IMS Health.
Schering-Plough's Nasonex, the nation's best INC seller,
will expire in 2014 at the earliest. “Nasonex sampling seems to be paying off.
[The product] is holding its own against a large generic threat,” says
Ramspacher. “Twenty-two percent of physicians overall prescribe [name brand]
Nasonex compared with 20% prescribing generics.” Nasonex is known by many for
its BBDO New York-created cartoon bee ads, which supersaturated consumer media
outlets beginning in 2004. A 2007 TV spot from the campaign was listed as the
fourth most-recalled ad by IAG Research. Despite criticism, the ads have
weathered negative attention, and have been refreshed with new creative – still
featuring the bee – for 2008.